Sio Gene Therapies Inc

Company Profile

Sio Gene Therapies Inc had its IPO on 2015-06-11 under the ticker symbol SIOX.

The company operates in the Healthcare sector and Biotechnology industry. Sio Gene Therapies Inc has a staff strength of 12 employees.

Stock update

Shares of Sio Gene Therapies Inc opened at $0.38 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.38 - $0.38, and closed at $0.38.

This is a 0% increase from the previous day's closing price.

A total volume of 4,005 shares were traded at the close of the day’s session.

In the last one week, shares of Sio Gene Therapies Inc have increased by 0%.

Sio Gene Therapies Inc's Key Ratios

Sio Gene Therapies Inc has a market cap of $28.11 million, indicating a price to book ratio of 0.5419 and a price to sales ratio of 0.

In the last 12-months Sio Gene Therapies Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-27152000. The EBITDA ratio measures Sio Gene Therapies Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sio Gene Therapies Inc’s operating margin was 0% while its return on assets stood at -24.34% with a return of equity of -47.5%.

In Q4, Sio Gene Therapies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Sio Gene Therapies Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.39 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sio Gene Therapies Inc’s profitability.

Sio Gene Therapies Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.4707. Its price to sales ratio in the trailing 12-months stood at 0.

Sio Gene Therapies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$47.27 million

Total Liabilities

$2.15 million

Operating Cash Flow

$0

Capital Expenditure

$290000

Dividend Payout Ratio

0%

Sio Gene Therapies Inc ended 2024 with $47.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $47.27 million while shareholder equity stood at $45.12 million.

Sio Gene Therapies Inc ended 2024 with $0 in deferred long-term liabilities, $2.15 million in other current liabilities, 1000.00 in common stock, $-878461000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $46.13 million and cash and short-term investments were $46.13 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Sio Gene Therapies Inc’s total current assets stands at $47.27 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $356000.00 compared to accounts payable of $201000.00 and inventory worth $0.

In 2024, Sio Gene Therapies Inc's operating cash flow was $0 while its capital expenditure stood at $290000.

Comparatively, Sio Gene Therapies Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.38

52-Week High

$0.465

52-Week Low

$0.26

Analyst Target Price

$5

Sio Gene Therapies Inc stock is currently trading at $0.38 per share. It touched a 52-week high of $0.465 and a 52-week low of $0.465. Analysts tracking the stock have a 12-month average target price of $5.

Its 50-day moving average was $0.39 and 200-day moving average was $0.4 The short ratio stood at 0.11 indicating a short percent outstanding of 0%.

Around 2530.2% of the company’s stock are held by insiders while 397.9% are held by institutions.